Park Ha Biological Technology Co., Ltd. Announces Closing of $2.0 Million Registered Direct Offering

Park Ha Biological Technology (NASDAQ: BYAH) closed a registered direct offering, selling up to 1,133,332 Class A ordinary shares and pre-funded warrants to buy 200,000 shares at $1.50 per share/warrant unit.

Rhea-AI Summary

Park Ha Biological Technology (NASDAQ: BYAH) closed a registered direct offering, selling up to 1,133,332 Class A ordinary shares and pre-funded warrants to buy 200,000 shares at $1.50 per share/warrant unit.

The company expects gross proceeds of about $2.0 million, before fees and expenses, for general corporate and working capital purposes.

Positive

• Raises approximately $2.0 million in gross proceeds to fund operations
• Issuance structure includes 1,133,332 shares plus 200,000 pre-funded warrants at $1.50
• Net proceeds earmarked for general corporate and working capital purposes

Negative

• New equity and warrant issuance may dilute existing shareholders
• Gross proceeds of $2.0 million will be reduced by fees and expenses

Market Context

This announcement details a registered direct offering for $2.0 million, involving 1,133,332 Class A...

Analysis

This announcement details a registered direct offering for $2.0 million, involving 1,133,332 Class A ordinary shares and pre-funded warrants for 200,000 additional shares at $1.50. The proceeds are earmarked for general corporate and working capital purposes. Investors may compare this equity issuance to the company’s depressed trading level near its 0.3573 52-week low and its substantial gap below the 8.17 200-day moving average, alongside prior Nasdaq deficiency notices.

Key Figures

Shares Offered: 1,133,332 Class A ordinary shares Pre-Funded Warrants: 200,000 shares underlying Offering Price: $1.50 per share and pre-funded warrant +5 more

Shares Offered

1,133,332 Class A ordinary shares

Aggregate amount in registered direct offering

Pre-Funded Warrants

200,000 shares underlying

Pre-funded warrants to purchase Class A ordinary shares

Offering Price

$1.50 per share and pre-funded warrant

Combined purchase price in registered direct offering

Gross Proceeds

$2.0 million

Before placement agent fees and offering expenses

Par Value

$0.001 per Class A ordinary share

Stated par value of Class A ordinary shares

Form Number

File No. 333-295090

SEC file number for Form F-3 registration statement

F-3 Effective Date

June 8, 2026

Date Form F-3 was declared effective by the SEC

52-Week Range

High <b>41.49</b>, Low <b>0.3573</b>

Pre-offering trading range from market_context

Key Terms

registered direct offering, pre-funded warrants, form f-3, prospectus supplement

4 terms

registered direct offering financial

"announced the closing of its previously announced registered direct offering with several investors"

A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.

pre-funded warrants financial

"and pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 200,000 Class A Ordinary Shares"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

form f-3 regulatory

"pursuant to an effective “shelf” registration statement on Form F-3 (File No. 333-295090)"

Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.

prospectus supplement regulatory

"The prospectus supplement describing the terms of the public offering was filed with the SEC."

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Wuxi, China, June 15, 2026 (GLOBE NEWSWIRE) -- Park Ha Biological Technology Co., Ltd., (NASDAQ: BYAH) an exempted company with limited liability incorporated under the laws of the Cayman Islands (the “Company”), today announced the closing of its previously announced registered direct offering with several investors for the sale and purchase of an aggregate of up to 1,133,332 of the Company’s Class A ordinary shares, par value $0.001 each (the “Class A Ordinary Shares”), and pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 200,000 Class A Ordinary Shares, at a combined purchase price of $1.50 per Class A Ordinary Share and Pre-Funded Warrant.

The gross proceeds to the Company from the registered direct offering are estimated to be approximately $2.0 million, before deducting the placement agent’s fees and other estimated offering expenses.

D. Boral Capital LLC acted as the sole placement agent for the offering. Concord & Sage PC acted as counsel to the Company. Hunter Taubman Fischer & Li LLC acted as US securities counsel to the placement agent.

The Company intends to use the net proceeds from this offering for general corporate and working capital purposes.

The offering of the securities described above were offered by the Company pursuant to an effective “shelf” registration statement on Form F-3 (File No. 333-295090) filed by the Company with the U.S. Securities and Exchange Commission (“SEC”) and declared effective by the SEC on June 8, 2026, and the accompanying prospectus contained therein.

The offering was made only by means of a prospectus supplement and accompanying prospectus. The prospectus supplement describing the terms of the public offering was filed with the SEC. Copies of the prospectus supplement and the accompanying prospectus relating to this offering may be obtained on the SEC’s website at http://www.sec.gov or by contacting D. Boral Capital LLC, 590 Madison Avenue, 39th Floor New York, NY 10022. For more detailed description of the securities in this offering please refer to the Company’s SEC filings at: https://www.sec.gov/edgar/search/#/ciks=0001986247&entityName=Park%2520Ha%2520Biological%2520Technology%2520Co.%252C%2520Ltd.%2520(BYAH)%2520(CIK%25200001986247)

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About the Company

Established in 2016, Park Ha Biological Technology Co., Ltd. is primarily engaged in developing its private skincare label, direct skincare products sales and franchise alliances promotions under the proprietary brand “Park Ha”, with a commitment to providing cost-effective solutions to skin problems and improving the confidence of women in need of skin treatment. As of October 31, 2025, the Company has five directly operated stores and 22 franchisees in China. As part of its value-added service for the products, the Company offers “light beauty experience”, a quick complimentary after-sales beauty service performed in the directly operated stores and franchise stores. For more information, please visit the Company’s website: http://ir.parkha.cn/. 

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may”, “will”, “expect”, “anticipate”, “aim”, “estimate”, “intend”, “plan”, “believe”, “is/are likely to”, “potential”, “continue” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC.

For more information, please contact:

D. Boral Capital LLC
590 Madison Avenue, 39th Floor
New York, NY 10022
Main Phone: +1 (212) 970-5150
www.dboralcapital.com
dbccapitalmarkets@dboralcapital.com 

Park Ha Biological Technology Co., Ltd.
901 & 901-2, Building C
Phase 2, Wuxi International Life Science Innovation Campus
196 Jinghui East Road
Xinwu District, Wuxi, Jiangsu Province
People’s Republic of China 214000
http://ir.parkha.cn/
ir_parkha@163.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Park Ha Biological Technology (NASDAQ: BYAH) announce on June 15, 2026 regarding a direct offering?

Park Ha Biological Technology announced closing a registered direct offering raising about $2.0 million in gross proceeds. According to the company, it sold up to 1,133,332 Class A ordinary shares and pre-funded warrants to purchase 200,000 shares at a combined price of $1.50.

How many shares are included in Park Ha Biological Technology's June 2026 registered direct offering (BYAH)?

The transaction covers up to 1,133,332 Class A ordinary shares and pre-funded warrants for 200,000 additional shares. According to the company, all securities were priced at a combined purchase price of $1.50 per Class A ordinary share and pre-funded warrant unit.

What is the total gross proceeds of Park Ha Biological Technology's June 2026 offering (BYAH)?

The offering is expected to generate approximately $2.0 million in gross proceeds before fees. According to the company, this figure is before deducting placement agent compensation and other estimated offering expenses tied to the registered direct transaction.

How will Park Ha Biological Technology use the proceeds from its June 2026 registered direct offering?

The company plans to use net proceeds for general corporate and working capital purposes. According to the company, funds from the approximately $2.0 million gross offering will support day-to-day operations and other unspecified corporate needs rather than a single defined project.

At what price were Park Ha Biological Technology's shares and pre-funded warrants sold in the June 2026 offering?

Each Class A ordinary share and pre-funded warrant unit was priced at a combined $1.50. According to the company, this pricing applied to up to 1,133,332 shares and pre-funded warrants exercisable for 200,000 additional Class A ordinary shares.

Who acted as placement agent for Park Ha Biological Technology's June 2026 registered direct offering?

D. Boral Capital acted as sole placement agent for the offering. According to the company, the transaction also involved Concord & Sage as company counsel and Hunter Taubman Fischer & Li as U.S. securities counsel to the placement agent.